February 10, 2020 / 11:35 AM / in 15 days

BRIEF-Axovant Gene Therapies Posts Q3 Loss Per Share Of $0.62

Feb 10 (Reuters) - Axovant Gene Therapies Ltd:

* AXOVANT ANNOUNCES FINANCIAL RESULTS FOR THIRD FISCAL QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2019

* Q3 LOSS PER SHARE $0.62

* Q3 EARNINGS PER SHARE ESTIMATE $-0.67 — REFINITIV IBES DATA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below